Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy and safety of lenvatinib combined with tislelizumab in fumarate hydratase-deficient renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fumarate Hydratase-deficient Renal Cell Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: RenJi Hospital | Conditions: Fumarate Hydratase Deficient Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN